Mumbai-based pharma major Lupin has launched Liraglutide Injection in US to help adults and children with type 2 diabetes manage their blood sugar levels. Shares of Lupin Ltd ended lower on Friday, October 03, by 0.32% at ₹1,975 on NSE.
Mumbai-based pharma major Lupin has launched Liraglutide Injection in US to help adults and children with type 2 diabetes manage their blood sugar levels. Shares of Lupin Ltd ended lower on Friday, October 03, by 0.32% at ₹1,975 on NSE.